Search Results

Bavarian Nordic A/S announced the initial safety and immunogenicity results from a randomized, double-blind, placebo-controlled Phase 3 clinical trial of a virus-like particle -based chikungunya virus vaccine candidate CHIKV VLP in healthy adults ≥65 years of age.

HilleVax, Inc. and Chengdu Kanghua Biological Products Co., Ltd. announced the entry into an exclusive license agreement for rights to Kangh’s hexavalent virus-like particle vaccine candidate for norovirus, referred to by HilleVax as HIL-216, outside of Greater China.

PathoVax LLC (“PathoVax”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for its licensed monovalent component- HPV16 RG1-VLP and concluded that a Phase 1 clinical trial in the United States and Austria is now given the go-ahead to proceed.

Allergy Therapeutics plc (“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut.

US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21 million in a Series A-1 round.

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV).

Blue Water Vaccines Inc. today announced that the Company plans to explore the potential to develop a novel monkeypox vaccine using its norovirus shell and protrusion virus-like particle (VLP) platform.

Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Icosavax, Inc. announced positive topline interim results from its Phase 2 clinical trial of IVX-A12 against respiratory syncytial virus and human metapneumovirus in older adults.